AstraZeneca to invest $50bn in US by 2030 amid Trump tariff threats
Briefly

AstraZeneca will invest $50bn in the US by 2030, funding a new drug manufacturing facility in Virginia and expanding research and development in several states. This move is in response to potential tariffs of up to 200% on imports imposed by the Trump administration. AstraZeneca's CEO stated that this investment supports the company's revenue goal of $80bn by 2030, with half of the sales expected to come from the US. Other pharmaceutical companies, like Roche and Novartis, are making similar investments due to these tariff threats.
AstraZeneca's $50bn investment aims to establish a new drug manufacturing facility in Virginia and expand research and development across various US states, highlighting a significant commitment to US operations in response to looming tariffs on foreign pharmaceuticals.
The investment aligns with AstraZeneca's goal of achieving $80bn in revenues by 2030, driven by an anticipated 50% of sales from the US market, underscoring the company's strategic focus on domestic manufacturing.
Read at www.theguardian.com
[
|
]